Management of diabetic kidney disease (DKD) has evolved in parallel with our growing
understanding of the multiple interrelated pathophysiological mechanisms that involve …

Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that
ultimately develops into end-stage kidney disease (ESKD) when not managed …

Importance An initial decline in estimated glomerular filtration rate (eGFR) is expected after
initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed …

Aims Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors reduce the risk of heart failure
(HF) events regardless of diabetes status. However, factors associated with their efficacy in …

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve
cardiovascular and renal outcomes in patients with established cardiovascular disease …

More than 20 years ago, we wrote a review evaluating whether or not angiotensin-
converting enzyme inhibitor (ACE)-associated elevations in serum creatinine were of …

Aim Sodium‐glucose cotransporter 2 (SGLT2) inhibitors often cause a transient decrease in
glomerular filtration rate (GFR) shortly after the initiation, referred to as the 'initial drop' …

Summary Heart failure (HF), diabetes, and chronic kidney disease (CKD) frequently coexist,
with one comorbidity worsening the prognosis of another. β-blockers, angiotensin-receptor …

Pharmacologic interventions to slow chronic kidney disease progression, such as ACE-
inhibitors, angiotensin receptor blockers, or sodium glucose co-transporter 2 inhibitors, often …

Background The initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) typically
leads to a reversible initial dip in estimated glomerular filtration rate (eGFR). The …